Related Experiment Video
Updated: Feb 11, 2026
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
Published on: June 5, 2020
Hepatitis C virus infection in kidney transplantation-changing paradigms with novel agents
Yuvaram N V Reddy1, David Nunes2, Vipul Chitalia3
1Department of Medicine, Boston University Medical Center, Boston, Massachusetts, USA.
Insights
New oral antiviral therapies offer highly effective and well-tolerated treatment for Hepatitis C virus (HCV) in kidney transplant patients, improving outcomes and reducing rejection risks. This marks a significant advancement over older interferon-based treatments.
Area of Science:
- Nephrology
- Hepatology
- Transplant Surgery
Background:
- Hepatitis C virus (HCV) significantly increases morbidity and mortality in kidney transplant recipients.
- HCV is linked to posttransplant glomerulonephritis, chronic allograft nephropathy, and New Onset Diabetes after Transplant (NODAT).
- Previous interferon-based therapies for HCV were poorly tolerated and associated with adverse effects, including rejection risk.
Purpose of the Study:
- To review the epidemiology of HCV in kidney transplantation.
- To discuss the impact of new oral direct-acting antiviral (DAA) therapies.
- To explore future research directions in HCV and transplantation.
Main Methods:
- Literature review of HCV epidemiology in kidney transplant patients.
- Analysis of current oral direct-acting antiviral (DAA) therapies.
- Discussion of treatment outcomes and implications for transplantation.
Main Results:
- Oral DAAs are highly effective (>90% sustained viral response) and well-tolerated for all HCV genotypes.
- DAAs minimize side-effects and the risk of acute rejection associated with prior interferon therapies.
- Potential for improved graft and patient survival and better organ allocation strategies.
Conclusions:
- Oral DAAs represent a paradigm shift in managing HCV in kidney transplant patients.
- These agents offer improved safety and efficacy, enhancing patient and graft outcomes.
- Further research is needed to optimize DAA use and explore long-term benefits in transplantation.
Abstract:
Hepatitis C virus (HCV) is a common cause of increased morbidity and mortality in kidney transplant patients. It is associated with posttransplant glomerulonephritis, chronic allograft nephropathy, and New Onset Diabetes after Transplant (NODAT). In the past, HCV was difficult to treat due to the presence of interferon alpha-based therapies that were difficult to tolerate and were associated with adverse side-effects, such as the risk of rejection. With the advent of oral directly acting antiviral therapies, the landscape for HCV and transplantation has changed. These agents are highly effective and well tolerated with minimal side-effects. Sustained viral response rates in excess of 90% are achieved with most current treatment regimens active against all HCV genotypes. These new agents may show an improvement in graft and patient survival while essentially eliminating the risk of acute rejection from the use of prior interferon-based HCV therapies. These agents may also result in an improvement in organ allocation for HCV donor/HCV recipient transplantation. This review is meant to discuss the epidemiology of HCV, the new oral direct-acting antiviral agents (DAAs) and future opportunities for research in the field of HCV related transplantation.
Related Concept Videos
01:28Kidney Transplant I: Introduction
01:26Kidney Transplant II: Surgical Procedure
01:16Kidney Transplant III: Nursing Management
01:45Kidney Structure
00:50What are Viruses?
01:50Global Climate Change